Testing is available for non-resectable, metastatic melanoma, by either Focus Panel or Oncopanel multigene NGS panel. Only one of these tests should be selected, both cannot be performed.

Both assays can detect targetable mutations in genes other than BRAF, including KIT, GNAQ and NRAS.

Targeted BRAF V600 testing is available for stage III melanoma.